Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Xvivo Perfusion AB's Days Payable or its related term are showing as below:
STU:3XV'
s Days Payable Range Over the Past 10 Years
Min: 46.32 Med: 92.95 Max: 123.69
Current: 46.32
During the past 13 years, Xvivo Perfusion AB's highest Days Payable was 123.69. The lowest was 46.32. And the median was 92.95.
STU:3XV's Days Payable is ranked worse than 60.75% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs STU:3XV: 46.32
Xvivo Perfusion AB's Days Payable
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
stayed the same
Xvivo Perfusion AB Days Payable Related Terms
Xvivo Perfusion AB Days Payable Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Xvivo Perfusion AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (STU:3XV) has a Days Payable of 0.00 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Xvivo Perfusion AB and its competitors. Over the past decade, Xvivo Perfusion AB's Days Payable has ranged from 46.32 to 123.69. According to the industry distribution chart, Xvivo Perfusion AB ranks #483 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 60.8%.
Is Xvivo Perfusion AB's Days Payable too high?
Xvivo Perfusion AB's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 46.32 to a high of 123.69. Based on the distribution chart, Xvivo Perfusion AB ranks #483 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #483 out of 795 companies for Days Payable. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Days Payable is 67.87. Historically, Xvivo Perfusion AB's own Days Payable has ranged from 46.32 to 123.69 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Xvivo Perfusion AB (STU:3XV) has a current Days Payable of 0.00. The stock's GF Value™ is €35.83, compared to a current price of €23.04 — trading 35.7% below its estimated fair value. The current Days Payable is 0.00. Xvivo Perfusion AB's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Xvivo Perfusion AB (STU:3XV), the current Days Payable is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (STU:3XV) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of €23.04 is trading 35.7% below its estimated GF Value™ of €35.83.
Key valuation signals for STU:3XV:
Days Payable: 0.00
GF Value™: €35.83 vs. price of €23.04 (35.7% below fair value)
No single metric tells the full story. See the STU:3XV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
90GF Score
Get the complete analysis for STU:3XV
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3XV has been successfully added to your 
